(VIANEWS) - Shares of BIOSENIC (BEL 20: BIOS.BR) experienced a sharp 25.37% decline over ten trading sessions, falling from EUR0.05 to EUR0.04 by 14:07 EST on Tuesday - marking their second consecutive session of losses. Meanwhile, BEL 20, one of France's major stock market indexes saw its index fall 2.05% to EUR3,487.36, in line with this downward trend seen the previous day.
About BIOSENIC
BioSenic S.A. is a biotech company focused on allogeneic cell and gene therapy. Their technologies include an exclusive bone marrow-sourced mesenchymal stromal cell platform as well as Arsenic TriOxide for immuno-oncology treatments. ALLOB and ArsciCor investigational medicinal products are currently undergoing Phase IIb and III trials respectively for treating difficult tibial fractures as well as Graft-versus-host disease; with headquarters located in Mont-Saint-Guibert Belgium they lead innovation biotechnology solutions at their forefront.
Technical Analysis
BIOSENIC's stock, bearing the symbol BIOS, experienced a decline in volume today with only 214,950 shares traded - 56.44% lower than its 30-day average volume of 1,209,210. This may signal lack of interest or activity surrounding BIOSENIC stock. BioSENIC stock volatility was measured as follows. Over the past week, month, and quarter, its intraday variation average was negative 0.24%; for months and quarters respectively they averaged negative 0.93% with positive 8.26% respectively as their highest amplitude of average volatility at 2.14% for week 1, 5.444% for month one and 8.26% for quarter two respectively. BIOSENIC stock appears to be overbought according to its stochastic oscillator reading of 80 or higher; investors should be wary of this sign as it could indicate an imminent price correction in BIOSENIC's stock. BIOSENIC stock has shown signs of decreased activity and may currently be considered overbought. Investors may wish to closely observe its performance over the coming days and weeks in order to ascertain their best course of action.
Equity Analysis
Based on available data, BIOSENIC has reported an earnings per share (EPS) figure of EUR7.53. This indicates that they generated a profit of EUR7.53 over the last twelve months per share. BIOSENIC currently boasts an attractive trailing twelve months PE ratio of 0.01. This indicates that its share price is trading at an extremely affordable valuation relative to annual earnings; for every euro of annual profits earned, one share purchases represent just EUR0.01 of investment capital. Based on this information, BIOSENIC may present an appealing investment opportunity - particularly if earnings growth is anticipated for the foreseeable future. Before making any definitive investment decisions regarding BIOSENIC it would be prudent to conduct further analysis and consider other relevant aspects such as its financial health and competitive standing.
More news about BIOSENIC (BIOS.BR).